retatrutide cause cancer The power of three: Retatrutide's role in modern obesity and diabetes therapy Female Obesity & Cancer |

Heart palpitations can occur during GLP-1 therapy, but understanding the mechanisms and proper monitoring helps minimize risk

Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) have cardiovascular benefits in type 2 diabetes, but none of the cardiovascular trials studied atrial fibrillation/atrial flutter (AF) as a primary endpoint

Conclusions These findings inform and contextualize future studies assessing cardiorenal outcomes for these and additional treatments, including finerenone, for individuals with CKD and type 2 diabetes

Since GLP-1 RAs improve both morning surge and nocturnal hypertension, they are expected as promising remedies for morning hypertension

After a median follow-up of 2.5 years, GLP-1 RAs users had lower risks of mortality (adjusted hazard ratio (aHR), 0.39

It also attempts to minimize the need for obesity care and obesity treatment